---
annotation-target: fonc-12-854192(1).pdf
---


>%%
>```annotation-json
>{"created":"2022-08-08T03:01:44.453Z","text":"发芽","updated":"2022-08-08T03:01:44.453Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":524,"end":531},{"type":"TextQuoteSelector","exact":"Sprouty","prefix":"ical University, Shenyang, China","suffix":"-related, EVH1 domain-containing"}]}]}
>```
>%%
>*%%PREFIX%%ical University, Shenyang, China%%HIGHLIGHT%% ==Sprouty== %%POSTFIX%%-related, EVH1 domain-containing*
>%%LINK%%[[#^fd5n3wa0kjl|show annotation]]
>%%COMMENT%%
>发芽
>%%TAGS%%
>
^fd5n3wa0kjl


>%%
>```annotation-json
>{"created":"2022-08-08T03:02:56.903Z","updated":"2022-08-08T03:02:56.903Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":574,"end":827},{"type":"TextQuoteSelector","exact":"(SPRED1) has been identified as anovel tumor suppressor gene in acute myeloid leukemia (AML). Previous studies showedthat SPRED1 methylation levels were significantly increased in AML patients, making it aninteresting candidate for further investigation","prefix":"VH1 domain-containing protein 1 ","suffix":"s. To confirm the association of"}]}]}
>```
>%%
>*%%PREFIX%%VH1 domain-containing protein 1%%HIGHLIGHT%% ==(SPRED1) has been identified as anovel tumor suppressor gene in acute myeloid leukemia (AML). Previous studies showedthat SPRED1 methylation levels were significantly increased in AML patients, making it aninteresting candidate for further investigation== %%POSTFIX%%s. To confirm the association of*
>%%LINK%%[[#^7u7b2g7hgjh|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^7u7b2g7hgjh


>%%
>```annotation-json
>{"created":"2022-08-08T03:03:10.607Z","updated":"2022-08-08T03:03:10.607Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":1028,"end":1065},{"type":"TextQuoteSelector","exact":" in a largercohort of 75 AML patients","prefix":"outcome, we conducted this study","suffix":". Significantly increased methyl"}]}]}
>```
>%%
>*%%PREFIX%%outcome, we conducted this study%%HIGHLIGHT%% ==in a largercohort of 75 AML patients== %%POSTFIX%%. Significantly increased methyl*
>%%LINK%%[[#^0dpgsuh9pm4s|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0dpgsuh9pm4s


>%%
>```annotation-json
>{"created":"2022-08-08T03:03:28.105Z","updated":"2022-08-08T03:03:28.105Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":1143,"end":1250},{"type":"TextQuoteSelector","exact":" ten CpG units by quantitative high-resolution mass spectrometry-based approach (MassARRAY) in AML patients","prefix":"f SPRED1 weredetected at four of","suffix":". Whereas overall survival (OS) "}]}]}
>```
>%%
>*%%PREFIX%%f SPRED1 weredetected at four of%%HIGHLIGHT%% ==ten CpG units by quantitative high-resolution mass spectrometry-based approach (MassARRAY) in AML patients== %%POSTFIX%%. Whereas overall survival (OS)*
>%%LINK%%[[#^xrrooewz9f|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xrrooewz9f


>%%
>```annotation-json
>{"created":"2022-08-08T03:03:46.437Z","updated":"2022-08-08T03:03:46.437Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":1401,"end":1526},{"type":"TextQuoteSelector","exact":"the relationship between methylation level andtreatment response was indicated in paired samples from pre- and post-induction","prefix":"nand hypomethylation subgroups, ","suffix":". Todetermine the possible mecha"}]}]}
>```
>%%
>*%%PREFIX%%nand hypomethylation subgroups,%%HIGHLIGHT%% ==the relationship between methylation level andtreatment response was indicated in paired samples from pre- and post-induction== %%POSTFIX%%. Todetermine the possible mecha*
>%%LINK%%[[#^n89enlgcyj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^n89enlgcyj


>%%
>```annotation-json
>{"created":"2022-08-08T03:04:11.402Z","text":"THP-1细胞系是从一名患有急性单核细胞白血病的1岁小男孩的外周血中分离得到的，自1980年建系以来，THP-1细胞被广泛用于单核细胞和巨噬细胞相关的机制、信号通路以及营养和药物运输等研究中。相对于U937、HL-60、ML-2等白血病细胞系，THP-1更有类似人原代单核细胞的形态和功能特征（包括细胞分化标记）。相对于人外周血单核细胞（PBMC），THP-1更易在实验室中培养和扩增，且具有更稳定的基因背景，不存在PBMC的个体差异性问题，利于实验结果的重现。因此，THP-1是各大实验室常用的急性单核细胞白血病细胞系，是研究免疫和炎症的理想工具。\nTHP-1与人原代单核细胞都可以被诱导分化为巨噬细胞M1和M2，并释放相应的细胞因子。","updated":"2022-08-08T03:04:11.402Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":1595,"end":1643},{"type":"TextQuoteSelector","exact":" performed in vitroexperiments using THP-1 cells","prefix":"of SPRED1 methylation in AML, we","suffix":", as the latter showed the highe"}]}]}
>```
>%%
>*%%PREFIX%%of SPRED1 methylation in AML, we%%HIGHLIGHT%% ==performed in vitroexperiments using THP-1 cells== %%POSTFIX%%, as the latter showed the highe*
>%%LINK%%[[#^cw6hiluiha|show annotation]]
>%%COMMENT%%
>THP-1细胞系是从一名患有急性单核细胞白血病的1岁小男孩的外周血中分离得到的，自1980年建系以来，THP-1细胞被广泛用于单核细胞和巨噬细胞相关的机制、信号通路以及营养和药物运输等研究中。相对于U937、HL-60、ML-2等白血病细胞系，THP-1更有类似人原代单核细胞的形态和功能特征（包括细胞分化标记）。相对于人外周血单核细胞（PBMC），THP-1更易在实验室中培养和扩增，且具有更稳定的基因背景，不存在PBMC的个体差异性问题，利于实验结果的重现。因此，THP-1是各大实验室常用的急性单核细胞白血病细胞系，是研究免疫和炎症的理想工具。
>THP-1与人原代单核细胞都可以被诱导分化为巨噬细胞M1和M2，并释放相应的细胞因子。
>%%TAGS%%
>
^cw6hiluiha


>%%
>```annotation-json
>{"created":"2022-08-08T03:06:55.090Z","text":"Lentiviral transduction is an efficient method for the delivery of transgenes to mammalian cells and unifies the ease of use and speed of transient transfection with the robust expression of stable cell lines. \n[protocol](https://pharm.ucsf.edu/xinchen/protocols/lv-transfection)","updated":"2022-08-08T03:06:55.090Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":1812,"end":1836},{"type":"TextQuoteSelector","exact":" lentivirus transfection","prefix":"sted.When treated with 5-AZA and","suffix":", upregulated SPRED1 expression,"}]}]}
>```
>%%
>*%%PREFIX%%sted.When treated with 5-AZA and%%HIGHLIGHT%% ==lentivirus transfection== %%POSTFIX%%, upregulated SPRED1 expression,*
>%%LINK%%[[#^5ilvoxf48dh|show annotation]]
>%%COMMENT%%
>Lentiviral transduction is an efficient method for the delivery of transgenes to mammalian cells and unifies the ease of use and speed of transient transfection with the robust expression of stable cell lines. 
>[protocol](https://pharm.ucsf.edu/xinchen/protocols/lv-transfection)
>%%TAGS%%
>
^5ilvoxf48dh


>%%
>```annotation-json
>{"created":"2022-08-08T03:09:45.047Z","updated":"2022-08-08T03:09:45.047Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":1837,"end":2048},{"type":"TextQuoteSelector","exact":" upregulated SPRED1 expression,decreased cell proliferation, increased cell differentiation and apoptosis, and inactivatedphosphorylated extracellular signal-regulated kinase (p-ERK) were detected in THP-1cells.","prefix":"AZA and lentivirus transfection,","suffix":" These results show that demethy"}]}]}
>```
>%%
>*%%PREFIX%%AZA and lentivirus transfection,%%HIGHLIGHT%% ==upregulated SPRED1 expression,decreased cell proliferation, increased cell differentiation and apoptosis, and inactivatedphosphorylated extracellular signal-regulated kinase (p-ERK) were detected in THP-1cells.== %%POSTFIX%%These results show that demethy*
>%%LINK%%[[#^dfndxfnzpci|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^dfndxfnzpci


>%%
>```annotation-json
>{"created":"2022-08-08T03:11:11.174Z","updated":"2022-08-08T03:11:11.174Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":4134,"end":4488},{"type":"TextQuoteSelector","exact":" However, there are still unknown factors for demethylatingtherapy, such as the duration of treatment, the markers ofdemethylating response, and the poor outcomes of treatment(10). One of the main reasons is that little is known about thetargets of demethylating agents themselves, and the specificgenes that are hypermethylated drive the leukemogenesis.","prefix":"ome specific types of AML (8,9).","suffix":"The Sprouty-related, EVH1 domain"}]}]}
>```
>%%
>*%%PREFIX%%ome specific types of AML (8,9).%%HIGHLIGHT%% ==However, there are still unknown factors for demethylatingtherapy, such as the duration of treatment, the markers ofdemethylating response, and the poor outcomes of treatment(10). One of the main reasons is that little is known about thetargets of demethylating agents themselves, and the specificgenes that are hypermethylated drive the leukemogenesis.== %%POSTFIX%%The Sprouty-related, EVH1 domain*
>%%LINK%%[[#^pzik3cuqdph|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^pzik3cuqdph


>%%
>```annotation-json
>{"created":"2022-08-08T03:12:12.354Z","updated":"2022-08-08T03:12:12.354Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":4574,"end":4828},{"type":"TextQuoteSelector","exact":"a member of the Sproutyprotein family and is phosphorylated by tyrosine kinase inresponse to several growth factors. Also, it is able to inhibit theRas/Raf/ERK pathway as a negative growth factor and isregulated by cytokine and chemokine-induced ERK (11)","prefix":"SPRED1) encoded by this gene is ","suffix":". In aprevious study, we have pr"}]}]}
>```
>%%
>*%%PREFIX%%SPRED1) encoded by this gene is%%HIGHLIGHT%% ==a member of the Sproutyprotein family and is phosphorylated by tyrosine kinase inresponse to several growth factors. Also, it is able to inhibit theRas/Raf/ERK pathway as a negative growth factor and isregulated by cytokine and chemokine-induced ERK (11)== %%POSTFIX%%. In aprevious study, we have pr*
>%%LINK%%[[#^73x7204mpd|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^73x7204mpd


>%%
>```annotation-json
>{"created":"2022-08-08T03:12:34.691Z","text":"what's this? ","updated":"2022-08-08T03:12:34.691Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":5018,"end":5034},{"type":"TextQuoteSelector","exact":"Legius syndrome ","prefix":"rst reported in achild AML with ","suffix":"(13), neither mutation nordeleti"}]}]}
>```
>%%
>*%%PREFIX%%rst reported in achild AML with%%HIGHLIGHT%% ==Legius syndrome== %%POSTFIX%%(13), neither mutation nordeleti*
>%%LINK%%[[#^tnfhob7wqe|show annotation]]
>%%COMMENT%%
>what's this? 
>%%TAGS%%
>#Legius syndrome is a condition characterized by changes in skin coloring (pigmentation). Almost all affected individuals have multiple café-au-lait spots, which are flat patches on the skin that are darker than the surrounding area.
^tnfhob7wqe


>%%
>```annotation-json
>{"created":"2022-08-08T03:13:30.285Z","updated":"2022-08-08T03:13:30.285Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":5199,"end":5223},{"type":"TextQuoteSelector","exact":"gatively correlated with","prefix":"hylatedin adult AMLs and were ne","suffix":" theexpression level of SPRED1 m"}]}]}
>```
>%%
>*%%PREFIX%%hylatedin adult AMLs and were ne%%HIGHLIGHT%% ==gatively correlated with== %%POSTFIX%%theexpression level of SPRED1 m*
>%%LINK%%[[#^q7cp8cg9ktq|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^q7cp8cg9ktq


>%%
>```annotation-json
>{"created":"2022-08-08T03:14:10.840Z","updated":"2022-08-08T03:14:10.840Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":6278,"end":6545},{"type":"TextQuoteSelector","exact":" The diagnosis andclassification were made according to the French-American-British (FAB) Cooperative Group criteria and WHOclassification (15). APL, which is the M3 subtype of FABcharacterizing those with t(15;17) or PML/RARA fusion gene,was excluded from this study","prefix":"5 years (range: 17 to 69 years).","suffix":".The follow-up of 71 patients wa"}]}]}
>```
>%%
>*%%PREFIX%%5 years (range: 17 to 69 years).%%HIGHLIGHT%% ==The diagnosis andclassification were made according to the French-American-British (FAB) Cooperative Group criteria and WHOclassification (15). APL, which is the M3 subtype of FABcharacterizing those with t(15;17) or PML/RARA fusion gene,was excluded from this study== %%POSTFIX%%.The follow-up of 71 patients wa*
>%%LINK%%[[#^57bqyb8kdpm|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^57bqyb8kdpm


>%%
>```annotation-json
>{"created":"2022-08-08T03:15:40.232Z","updated":"2022-08-08T03:15:40.232Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":6660,"end":6719},{"type":"TextQuoteSelector","exact":"theChinese expert consensus on the treatment of AML (2011).","prefix":"nd response assessment followed ","suffix":" Atotal of 13 patients received "}]}]}
>```
>%%
>*%%PREFIX%%nd response assessment followed%%HIGHLIGHT%% ==theChinese expert consensus on the treatment of AML (2011).== %%POSTFIX%%Atotal of 13 patients received*
>%%LINK%%[[#^1hwoikd4jg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^1hwoikd4jg


>%%
>```annotation-json
>{"created":"2022-08-08T03:15:51.450Z","updated":"2022-08-08T03:15:51.450Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":6813,"end":6837},{"type":"TextQuoteSelector","exact":" complete remission (CR)","prefix":"ansplantation (allo-HSCT) in the","suffix":"phase. CR was evaluated after th"}]}]}
>```
>%%
>*%%PREFIX%%ansplantation (allo-HSCT) in the%%HIGHLIGHT%% ==complete remission (CR)== %%POSTFIX%%phase. CR was evaluated after th*
>%%LINK%%[[#^6ab90cq3p87|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6ab90cq3p87


>%%
>```annotation-json
>{"created":"2022-08-08T03:16:44.519Z","updated":"2022-08-08T03:16:44.519Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":7025,"end":7073},{"type":"TextQuoteSelector","exact":"Human-AML cell lines HL-60, THP-1, and OCI-AML2 ","prefix":"(#AF-SOP-07-1.0-01).Cell Culture","suffix":"wereobtained from the American T"}]}]}
>```
>%%
>*%%PREFIX%%(#AF-SOP-07-1.0-01).Cell Culture%%HIGHLIGHT%% ==Human-AML cell lines HL-60, THP-1, and OCI-AML2== %%POSTFIX%%wereobtained from the American T*
>%%LINK%%[[#^42wcklbb6ct|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^42wcklbb6ct


>%%
>```annotation-json
>{"created":"2022-08-08T03:16:53.014Z","updated":"2022-08-08T03:16:53.014Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":7158,"end":7210},{"type":"TextQuoteSelector","exact":"ultured in Roswell Park MemorialInstitute (RPMI)-164","prefix":"n (ATCC,Manassas, VA, USA) and c","suffix":"0 (GIBCO, Grand Island, NY, USA)"}]}]}
>```
>%%
>*%%PREFIX%%n (ATCC,Manassas, VA, USA) and c%%HIGHLIGHT%% ==ultured in Roswell Park MemorialInstitute (RPMI)-164== %%POSTFIX%%0 (GIBCO, Grand Island, NY, USA)*
>%%LINK%%[[#^u7qy6990iij|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^u7qy6990iij


>%%
>```annotation-json
>{"created":"2022-08-08T03:17:16.949Z","updated":"2022-08-08T03:17:16.949Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":7895,"end":7951},{"type":"TextQuoteSelector","exact":" Yuanqi BiomedicalTechnology Co. Ltd. (Shanghai, China).","prefix":"samples with a Genoptix panel by","suffix":" The panel covers hotspots of 21"}]}]}
>```
>%%
>*%%PREFIX%%samples with a Genoptix panel by%%HIGHLIGHT%% ==Yuanqi BiomedicalTechnology Co. Ltd. (Shanghai, China).== %%POSTFIX%%The panel covers hotspots of 21*
>%%LINK%%[[#^rdgnopca8qc|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rdgnopca8qc


>%%
>```annotation-json
>{"created":"2022-08-08T03:19:04.806Z","updated":"2022-08-08T03:19:04.806Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":8549,"end":8588},{"type":"TextQuoteSelector","exact":"BGI TechSolutions Co. (Shanghai, China)","prefix":"platform (Sequenom, CA, USA) by ","suffix":". As a prediction, 12 CpG unitsw"}]}]}
>```
>%%
>*%%PREFIX%%platform (Sequenom, CA, USA) by%%HIGHLIGHT%% ==BGI TechSolutions Co. (Shanghai, China)== %%POSTFIX%%. As a prediction, 12 CpG unitsw*
>%%LINK%%[[#^fiepv9srlpk|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^fiepv9srlpk


>%%
>```annotation-json
>{"created":"2022-08-08T03:21:49.295Z","updated":"2022-08-08T03:21:49.295Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":30297,"end":30454},{"type":"TextQuoteSelector","exact":"Nowadays, the treatment strategies for AML are chosen based onage and prognostic stratification, which is determined bycytogenetic and molecular alterations ","prefix":"e 12 | Article 8541927DISCUSSION","suffix":"(16–18). Thanks torecent technol"}]}]}
>```
>%%
>*%%PREFIX%%e 12 | Article 8541927DISCUSSION%%HIGHLIGHT%% ==Nowadays, the treatment strategies for AML are chosen based onage and prognostic stratification, which is determined bycytogenetic and molecular alterations== %%POSTFIX%%(16–18). Thanks torecent technol*
>%%LINK%%[[#^bbd7z1r13v8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^bbd7z1r13v8


>%%
>```annotation-json
>{"created":"2022-08-08T03:22:36.888Z","updated":"2022-08-08T03:22:36.888Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":31104,"end":31356},{"type":"TextQuoteSelector","exact":"In our prior studies, we found that the expression of SPRED1was significantly reduced, which was closely related to thehypermethylation of SPRED1 in non-APL patients, and thepatients who obtained CR might be with decreasingmethylation level of SPRED1 (","prefix":"stent clinical response(24, 25).","suffix":"14). Also, our results indicated"}]}]}
>```
>%%
>*%%PREFIX%%stent clinical response(24, 25).%%HIGHLIGHT%% ==In our prior studies, we found that the expression of SPRED1was significantly reduced, which was closely related to thehypermethylation of SPRED1 in non-APL patients, and thepatients who obtained CR might be with decreasingmethylation level of SPRED1 (== %%POSTFIX%%14). Also, our results indicated*
>%%LINK%%[[#^awrazvlp5io|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^awrazvlp5io


>%%
>```annotation-json
>{"created":"2022-08-08T03:23:17.954Z","updated":"2022-08-08T03:23:17.954Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":33462,"end":33656},{"type":"TextQuoteSelector","exact":"Our previous pilot study has shown that SPRED1hypermethylation was related to some common AML genemutations, such as DNMT3A and TET2 (14), which wereresponse indicators for demethylation agents ","prefix":" is worth further investigation.","suffix":"(26, 27).However, in this study,"}]}]}
>```
>%%
>*%%PREFIX%%is worth further investigation.%%HIGHLIGHT%% ==Our previous pilot study has shown that SPRED1hypermethylation was related to some common AML genemutations, such as DNMT3A and TET2 (14), which wereresponse indicators for demethylation agents== %%POSTFIX%%(26, 27).However, in this study,*
>%%LINK%%[[#^ou28t86299|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ou28t86299


>%%
>```annotation-json
>{"created":"2022-08-08T03:23:37.771Z","updated":"2022-08-08T03:23:37.771Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":33665,"end":33942},{"type":"TextQuoteSelector","exact":"However, in this study, hypermethylation of SPRED1 is morefrequently presented in patients with an FLT3-ITD or NPM1mutation, but not gene mutations involving DNA methylation,indicating that hypermethylation of SPRED1 might mediateresistance to drug by a more complex mechanism.","prefix":"r demethylation agents (26, 27).","suffix":" Therefore,we determined the dem"}]}]}
>```
>%%
>*%%PREFIX%%r demethylation agents (26, 27).%%HIGHLIGHT%% ==However, in this study, hypermethylation of SPRED1 is morefrequently presented in patients with an FLT3-ITD or NPM1mutation, but not gene mutations involving DNA methylation,indicating that hypermethylation of SPRED1 might mediateresistance to drug by a more complex mechanism.== %%POSTFIX%%Therefore,we determined the dem*
>%%LINK%%[[#^ffdgpvv43cm|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ffdgpvv43cm


>%%
>```annotation-json
>{"created":"2022-08-08T03:24:23.988Z","updated":"2022-08-08T03:24:23.988Z","document":{"title":"Methylation of SPRED1: A New Target in Acute Myeloid Leukemia","link":[{"href":"urn:x-pdf:9201c3cec818beef6f7db5ddc987ced7"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf"}],"documentFingerprint":"9201c3cec818beef6f7db5ddc987ced7"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-12-854192(1).pdf","selector":[{"type":"TextPositionSelector","start":36002,"end":36315},{"type":"TextQuoteSelector","exact":"it will help us understand how SPRED1/ERK crosstalk signalingworks, which can probably support a new epigenetic therapytarget for AMLs. Meanwhile, whether the combination ofdemethylating agents and SPRED1 targeting agents can furtherimprove the efficacy of AML therapy needs further exploration inthe near future.","prefix":"cular markers. At the same time,","suffix":"DATA AVAILABILITY STATEMENTThe d"}]}]}
>```
>%%
>*%%PREFIX%%cular markers. At the same time,%%HIGHLIGHT%% ==it will help us understand how SPRED1/ERK crosstalk signalingworks, which can probably support a new epigenetic therapytarget for AMLs. Meanwhile, whether the combination ofdemethylating agents and SPRED1 targeting agents can furtherimprove the efficacy of AML therapy needs further exploration inthe near future.== %%POSTFIX%%DATA AVAILABILITY STATEMENTThe d*
>%%LINK%%[[#^wlth90jo95r|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^wlth90jo95r
